How suitable is intravenous tocilizumab for the treatment of Graves' ophthalmopathy?

Expert Rev Clin Immunol. 2021 Nov;17(11):1151-1153. doi: 10.1080/1744666X.2021.1997591. Epub 2021 Nov 1.

Authors

Maria Alejandra Mejía González^{1

2}, Javier Carbone^{1

2

3}

Affiliations

¹ Immunology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
² Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
³ Immunology, Ophthalmology and ENT Department, Universidad Complutense, Madrid, Spain.

PMID: 34704876
DOI: 10.1080/1744666X.2021.1997591

No abstract available

Keywords: Graves’ ophthalmopathy; glucocorticoids; immunotherapy; therapy; tocilizumab.

Publication types

Editorial

MeSH terms

Administration, Intravenous
Antibodies, Monoclonal, Humanized* / therapeutic use
Graves Ophthalmopathy* / drug therapy
Humans

Substances

Antibodies, Monoclonal, Humanized
tocilizumab